Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

被引：0
作者：
Sharma, Abhinav [1 ,14 ]
Marques, Pedro [1 ]
Neuen, Brendon L. [2 ,3 ]
Fletcher, Robert A. [2 ]
Slee, April [4 ]
Rapattoni, Wally [5 ]
Ang, Fernando G. [5 ]
Arnott, Clare [2 ,6 ,7 ,8 ]
Levin, Adeera [9 ]
Verma, Subodh [10 ,11 ]
Perkovic, Vlado [2 ,6 ,12 ]
Mahaffey, Kenneth W. [13 ]
机构：
[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[2] UNSW Sydney, George Inst Global Hlth, Sydney, Australia
[3] Royal North Shore Hosp, Sydney, Australia
[4] New Arch Consulting, Seattle, WA USA
[5] Janssen Inc, Toronto, ON, Canada
[6] UNSW Sydney, Fac Med, Sydney, NSW, Australia
[7] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, Australia
[8] Univ Sydney, Sydney Med Sch, Sydney, Australia
[9] Univ British Columbia, St Pauls Hosp, Div Nephrol, Vancouver, BC, Canada
[10] Univ Toronto, St Michaels Hosp, Div Cardiac Surg, Toronto, ON, Canada
[11] St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada
[12] Royal North Shore Hosp, Sydney, Australia
[13] Stanford Univ, Stanford Ctr Clin Res, Dept Med, Sch Med, Stanford, CA USA
[14] McGill Univ, Hlth Ctr, Div Cardiol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada
来源：
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 02期
关键词：
canagliflozin; cardiovascular; clinical trials; heart failure; timing of benefits;
D O I：
10.1111/dom.15340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：758 / 762
页数：5
相关论文
共 13 条
  • [1] Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
    Bedrouni, Wassim
    Sharma, Abhinav
    Pitt, Bertram
    Lam, Carolyn S. P.
    Ni, Jiayi
    Ferreira, Joao Pedro
    McMurray, John
    Giannetti, Nadia
    Girerd, Nicolas
    Rossignol, Patrick
    Solomon, Scott D.
    Claggett, Brian
    Pocock, Stuart
    Huynh, Thao
    Zannad, Faiez
    [J]. CIRCULATION-HEART FAILURE, 2022, 15 (10)
  • [2] Gliflozins in the Management of Cardiovascular Disease
    Braunwald, Eugene
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) : 2024 - 2034
  • [3] Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM) in patients in the ACCORD trial
    Elharram, Malik
    Ferreira, Joao Pedro
    Huynh, Thao
    Ni, Jiayi
    Giannetti, Nadia
    Verma, Subodh
    Zannad, Faiez
    Sharma, Abhinav
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03) : 782 - 790
  • [4] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Ofstad, Anne Pernille
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    Zannad, Faiez
    [J]. ESC HEART FAILURE, 2021, 8 (06): : 4517 - 4527
  • [5] How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? Completed and Ongoing Mechanistic Trials
    Lee, Matthew M. Y.
    Petrie, Mark C.
    McMurray, John J. V.
    Sattar, Naveed
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (03) : 506 - 522
  • [6] Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
    Li, JingWei
    Woodward, Mark
    Perkovic, Vlado
    Figtree, Gemma A.
    Heerspink, Hiddo J. L.
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Vercruysse, Frank
    Shaw, Wayne
    Matthews, David R.
    Neal, Bruce
    [J]. JACC-HEART FAILURE, 2020, 8 (01) : 57 - 66
  • [7] Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
    McGuire, Darren K.
    Shih, Weichung J.
    Cosentino, Francesco
    Charbonnel, Bernard
    Cherney, David Z. I.
    Dagogo-Jack, Samuel
    Pratley, Richard
    Greenberg, Michelle
    Wang, Shuai
    Huyck, Susan
    Gantz, Ira
    Terra, Steven G.
    Masiukiewicz, Urszula
    Cannon, Christopher P.
    [J]. JAMA CARDIOLOGY, 2021, 6 (02) : 148 - 158
  • [8] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Law, Gordon
    Desai, Mehul
    Matthews, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) : 644 - 657
  • [9] Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial
    Packer, Milton
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Brueckmann, Martina
    Jamal, Waheed
    Zeller, Cordula
    Schnaidt, Sven
    Zannad, Faiez
    [J]. CIRCULATION, 2021, 143 (04) : 326 - 336
  • [10] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
    Perkovic, V.
    Jardine, M. J.
    Neal, B.
    Bompoint, S.
    Heerspink, H. J. L.
    Charytan, D. M.
    Edwards, R.
    Agarwal, R.
    Bakris, G.
    Bull, S.
    Cannon, C. P.
    Capuano, G.
    Chu, P. -L.
    De Zeeuw, D.
    Greene, T.
    Levin, A.
    Pollock, C.
    Wheeler, D. C.
    Yavin, Y.
    Zhang, H.
    Zinman, B.
    Meininger, G.
    Brenner, B. M.
    Mahaffey, K. W.
    McGuire, Darren K.
    Holman, Rury
    Home, Philip
    Scharfstein, Dan
    Parfrey, Patrick
    Shahinfar, Shahnaz
    August, Phyllis
    Chang, Tara
    Sinha, Arjun D.
    Januzzi, James
    Kolansky, Daniel
    Amerena, John
    Hillis, Graham
    Gorelick, Philip
    Kissela, Brett
    Kasner, Scott
    Lindley, Richard
    Fulcher, Greg
    Ounadjela, Souhila
    Hufert, Karina
    von Ingersleben, Gabriele
    Gaglia, Jason
    Harris, Ronald
    Hudson, Margo
    Turchin, Alexander
    Cheifetz, Adam
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2295 - 2306
12